Metformin enhances differentiation and function of skeletal muscle in models of Facioscapulohumeral Muscular Dystrophy (FSHD)

Verdict. Metabolic perturbation, mitochondrial dysfunction, and oxidative stress are key contributors to FSHD pathology. It intersects mitochondrial stress/dysfunction themes (mitochondrial dysfunction; oxidative stress; reactive oxygen species).

What the authors report

Facioscapulohumeral muscular dystrophy (FSHD) is one of the most prevalent inherited muscular dystrophies, for which there are no disease-modifying therapies. Here, the effects of the metabolic regulator and anti-diabetic drug Metformin on myogenesis and muscle function in human and murine models of FSHD were investigated.

Key results stated in the abstract include the following. Metabolic perturbation, mitochondrial dysfunction, and oxidative stress are key contributors to FSHD pathology. Mechanistic interrogation revealed reduced levels of mitochondrial reactive oxygen species and modified mitochondrial turnover. These cellular investigations were complemented with in vivo functional assessment in a murine model of FSHD, in which Metformin treated mice exhibited significantly improved muscle strength.

Why it matters for mitochondrial biology

Within mitochondrial research, this work maps primarily to redox biology, metabolism, therapeutics, computational. It is relevant to mitochondrial dysfunction discourse because the abstract invokes mitochondrial dysfunction, oxidative stress, reactive oxygen species, disease context. That does not by itself establish a validated disease mechanism; it indicates thematic proximity. Because a therapeutic or interventional angle is present, the piece is of interest for mitochondrial-targeted drug hypothesis generation—subject to full-text validation of endpoints and safety context. Server: biorxiv. Posted 2026-07-31. Synthesis confidence is bounded by abstract completeness.

Study design (abstract-level)

Here, the effects of the metabolic regulator and anti-diabetic drug Metformin on myogenesis and muscle function in human and murine models of FSHD were investigated. Metformin did not affect the proliferation rate of human control or patient-derived FSHD myoblasts but promoted their myogenic differentiation, increasing myotube formation and maturation. These cellular investigations were complemented with in vivo functional assessment in a murine model of FSHD, in which Metformin treated mice exhibited significantly improved muscle strength.

Principal findings

1. Metabolic perturbation, mitochondrial dysfunction, and oxidative stress are key contributors to FSHD pathology.
2. Mechanistic interrogation revealed reduced levels of mitochondrial reactive oxygen species and modified mitochondrial turnover.
3. These cellular investigations were complemented with in vivo functional assessment in a murine model of FSHD, in which Metformin treated mice exhibited significantly improved muscle strength.
4. Collectively, these findings identify metabolic regulation as a therapeutically tractable feature of FSHD and demonstrate that Metformin improves muscle function in multiple models of FSHD via reduction of oxidative stress and augmentation of cellular metabolic fitness.
5. These results provide insight into the therapeutic actions of Metformin and pre-clinical data to support its testing for repurposing in FSHD.

Limitations of this brief

• This Mitos brief is an abstract-level synthesis of a preprint; it is not peer review and not a substitute for reading the full paper.
• Preprint status: findings may change with revision or journal review.
• Effect sizes, n numbers, statistics, and full experimental controls are typically incomplete at abstract resolution.
• Primary source: biorxiv DOI 10.64898/2026.07.30.736088 (posted 2026-07-31).

Open scientific questions

• Which specific experimental panels in the full paper establish the strongest causal claim, and how robust are the controls?
• What dose, timing, and off-target profile would be required to take the intervention seriously as a therapeutic hypothesis?
• How do these findings sit relative to prior literature on the same pathway—replication, contradiction, or incremental extension?

Bottom line

For mitochondrial biologists focused on redox biology, metabolism, therapeutics, this preprint is worth full-text review soon. Abstract-level takeaway: Metabolic perturbation, mitochondrial dysfunction, and oxidative stress are key contributors to FSHD pathology. Confirm methods, effect sizes, and controls in the full PDF before citing the result as established.

Bibliographic record

Abstract-based editorial synthesis by Mitos. Not peer review.